{"protocolSection": {"identificationModule": {"nctId": "NCT01307046", "orgStudyIdInfo": {"id": "0954A-352"}, "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)", "officialTitle": "A Phase III, Randomized, Active-comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954A in Japanese Patients With Essential Hypertension Uncontrolled With the High Dose of Losartan Potassium"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-03-29", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2012-02-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-02-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-03-01", "studyFirstSubmitQcDate": "2011-03-01", "studyFirstPostDateStruct": {"date": "2011-03-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-01-02", "resultsFirstSubmitQcDate": "2013-02-19", "resultsFirstPostDateStruct": {"date": "2013-03-22", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-08", "lastUpdatePostDateStruct": {"date": "2024-05-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is being conducted to evaluate the efficacy of MK-0954A in essential hypertension participants who are not adequately controlled with losartan."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Essential hypertension", "Uncontrolled hypertension", "Antihypertensive agents", "Blood pressure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 336, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MK-0954A", "type": "EXPERIMENTAL", "description": "Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.", "interventionNames": ["Drug: MK-0954A", "Drug: Placebo to losartan 100 mg", "Drug: Placebo to losartan 50 mg"]}, {"label": "Losartan", "type": "ACTIVE_COMPARATOR", "description": "Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.", "interventionNames": ["Drug: Losartan", "Drug: Placebo to MK-0954A", "Drug: Placebo to losartan 50 mg"]}], "interventions": [{"type": "DRUG", "name": "MK-0954A", "description": "Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily", "armGroupLabels": ["MK-0954A"]}, {"type": "DRUG", "name": "Losartan", "description": "Tablet containing losartan potassium (100 mg), once daily", "armGroupLabels": ["Losartan"]}, {"type": "DRUG", "name": "Placebo to MK-0954A", "description": "Placebo tablet to match MK-0954A, once daily", "armGroupLabels": ["Losartan"]}, {"type": "DRUG", "name": "Placebo to losartan 100 mg", "description": "Placebo tablet to match losartan 100 mg, once daily", "armGroupLabels": ["MK-0954A"]}, {"type": "DRUG", "name": "Placebo to losartan 50 mg", "description": "Placebo tablet to match losartan 50 mg, once daily", "armGroupLabels": ["Losartan", "MK-0954A"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP)", "description": "Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 \u00b1 2 hours after the last study drug administration (Day 56 \u00b1 7 days).", "timeFrame": "Baseline and Week 8"}, {"measure": "Percentage of Participants Who Experienced at Least One Adverse Event (AE)", "timeFrame": "8 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP)", "description": "Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 \u00b1 2 hours after the last study drug administration (Day 56 \u00b1 7 days).", "timeFrame": "Baseline and Week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Participant has a diagnosis of essential hypertension.\n* Participant is not treated with antihypertensive medication and meets protocol-specified blood pressure criteria.\n* Participant is treated with single antihypertensive medication, and meets protocol-specified blood pressure criteria.\n* Participant is being treated with up to dual oral antihypertensive medications, and will be able to discontinue the prior antihypertensive medication.\n* Participant has no clinically meaningful findings to be disqualified from the study at the discretion of the investigator.\n\nExclusion criteria:\n\n* Regarding hypertension, participant is currently taking \\> 2 antihypertensive medications.\n* Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-lotan or Preminent and thiazide drug or related drug (i.e., sulfonamide-containing \"chlortalidone\" medicines)\n* Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or a recent history within the last year of drug or alcohol abuse or dependence.\n* Participant is pregnant or breastfeeding or expecting to conceive or has a positive pregnancy test at the screening visit.\n* Participant is currently participating or has participated in a study with an investigational compound (except losartan at any doses) or device within 30 days of signing informed consent.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "referencesModule": {"references": [{"pmid": "24990091", "type": "RESULT", "citation": "Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguchi H, Fujimoto G, Azuma K, Shirakawa M, Hanson ME, Fujita KP. Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials. Hypertens Res. 2014 Dec;37(12):1042-9. doi: 10.1038/hr.2014.114. Epub 2014 Jul 3. Erratum In: Hypertens Res. 2014 Dec;37(12):1088."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MK-0954A", "description": "Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks."}, {"id": "FG001", "title": "Losartan", "description": "Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "166"}, {"groupId": "FG001", "numSubjects": "170"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "154"}, {"groupId": "FG001", "numSubjects": "159"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "11"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Serum Potassium Withdrawal Criteria Met", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Blood Pressure Withdrawal Criteria Met", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MK-0954A", "description": "Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks."}, {"id": "BG001", "title": "Losartan", "description": "Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "166"}, {"groupId": "BG001", "value": "170"}, {"groupId": "BG002", "value": "336"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.7", "spread": "9.2"}, {"groupId": "BG001", "value": "54.9", "spread": "9.5"}, {"groupId": "BG002", "value": "55.3", "spread": "9.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "97"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "129"}, {"groupId": "BG001", "value": "110"}, {"groupId": "BG002", "value": "239"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP)", "description": "Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 \u00b1 2 hours after the last study drug administration (Day 56 \u00b1 7 days).", "populationDescription": "Full Analysis Set (FAS) population: defined as all randomized participants who received at least one dose of study treatment, had at least one post-randomization observation for the analysis endpoint subsequent\n\nto at least one dose of study treatment, and had baseline data for those analyses that required baseline data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "MK-0954A", "description": "Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Losartan", "description": "Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "166"}, {"groupId": "OG001", "value": "170"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.7", "spread": "0.6", "lowerLimit": "-9.9", "upperLimit": "-7.6"}, {"groupId": "OG001", "value": "-3.6", "spread": "0.6", "lowerLimit": "-4.8", "upperLimit": "-2.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "constrained longitudinal data analysis", "paramType": "Difference in least square means", "paramValue": "-5.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.8", "ciUpperLimit": "-3.4"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP)", "description": "Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 \u00b1 2 hours after the last study drug administration (Day 56 \u00b1 7 days).", "populationDescription": "Full Analysis Set (FAS) Population: defined as all randomized participants who received at least one dose of study treatment, had at least one post-randomization observation for the analysis endpoint subsequent\n\nto at least one dose of study treatment, and had baseline data for those analyses that required baseline data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "MK-0954A", "description": "Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Losartan", "description": "Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "166"}, {"groupId": "OG001", "value": "170"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-14.5", "lowerLimit": "-16.5", "upperLimit": "-12.6"}, {"groupId": "OG001", "value": "-5.4", "lowerLimit": "-7.3", "upperLimit": "-3.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<.001", "statisticalMethod": "constrained longitudinal data analysis", "paramType": "Difference in least square means", "paramValue": "-9.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.9", "ciUpperLimit": "-6.5"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Who Experienced at Least One Adverse Event (AE)", "populationDescription": "All-Patients-as-Treated (APaT) Population: defined as all randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "MK-0954A", "description": "Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Losartan", "description": "Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "166"}, {"groupId": "OG001", "value": "170"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31.3"}, {"groupId": "OG001", "value": "26.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "MK-0954A", "description": "Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 166, "otherNumAffected": 9, "otherNumAtRisk": 166}, {"id": "EG001", "title": "Losartan", "description": "Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 170, "otherNumAffected": 9, "otherNumAtRisk": 170}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 9, "numAtRisk": 166}, {"groupId": "EG001", "numEvents": 10, "numAffected": 9, "numAtRisk": 170}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. The sponsor review can be expedited to meet publication timelines."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merch Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Japan"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21701", "name": "Losartan", "asFound": "Staff", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M9910", "name": "Hydrochlorothiazide", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}